96 related articles for article (PubMed ID: 7923321)
21. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
Lordick F; Ehlken B; Ihbe-Heffinger A; Berger K; Krobot KJ; Pellissier J; Davies G; Deuson R
Eur J Cancer; 2007 Jan; 43(2):299-307. PubMed ID: 17134890
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
Kwong WJ; Parasuraman TV
Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607
[TBL] [Abstract][Full Text] [Related]
23. Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial.
Walsh T; Morris AK; Holle LM; Callander N; Bradshaw P; Valley AW; Clark G; Freytes CO
Bone Marrow Transplant; 2004 Dec; 34(11):963-8. PubMed ID: 15489869
[TBL] [Abstract][Full Text] [Related]
24. Granisetron: is there a dose-response effect on nausea and vomiting?
Minami M
Cancer Chemother Pharmacol; 2003 Aug; 52(2):89-98. PubMed ID: 12783208
[TBL] [Abstract][Full Text] [Related]
25. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
26. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
27. Controlling conditioning-related emesis in children undergoing bone marrow transplantation.
Mehta NH; Reed CM; Kuhlman C; Weinstein HJ; Parsons SK
Oncol Nurs Forum; 1997 Oct; 24(9):1539-44. PubMed ID: 9348595
[TBL] [Abstract][Full Text] [Related]
28. Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis.
Barrajon E; de las Peñas R
Support Care Cancer; 2000 Jul; 8(4):323-33. PubMed ID: 10923774
[TBL] [Abstract][Full Text] [Related]
29. [Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin].
Harousseau JL
Bull Cancer; 1996 Jan; 83(1):71-76. PubMed ID: 8672859
[TBL] [Abstract][Full Text] [Related]
30. Granisetron.
Ignoffo RJ
Cancer Pract; 1994; 2(3):229-31. PubMed ID: 8055027
[TBL] [Abstract][Full Text] [Related]
31. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting.
Zbrozek AS; Cantor SB; Cardenas MP; Hill DP
Am J Hosp Pharm; 1994 Jun; 51(12):1555-63. PubMed ID: 8092156
[TBL] [Abstract][Full Text] [Related]
32. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
33. Review of experience with ondansetron and granisetron.
Aapro MS
Ann Oncol; 1993; 4 Suppl 3():9-14. PubMed ID: 8395875
[TBL] [Abstract][Full Text] [Related]
34. Cost effectiveness of 5-hydroxytryptamine3 receptor antagonists: a retrospective comparison of ondansetron and granisetron.
Johnson N; Bosanquet N
Anticancer Drugs; 1995 Apr; 6(2):243-9. PubMed ID: 7795273
[TBL] [Abstract][Full Text] [Related]
35. A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis.
Perez EA
Drug Saf; 1998 Jan; 18(1):43-56. PubMed ID: 9466087
[TBL] [Abstract][Full Text] [Related]
36. Always more "setrons": how many do we need?
Aapro MS
Support Care Cancer; 1997 Jan; 5(1):1-2. PubMed ID: 9010981
[No Abstract] [Full Text] [Related]
37. The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis.
Jones AL; Lee GJ; Bosanquet N
Eur J Cancer; 1992; 29A(1):51-6. PubMed ID: 1332738
[TBL] [Abstract][Full Text] [Related]
38. A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation.
Gibbs SJ; Cassoni AM
Clin Oncol (R Coll Radiol); 1996; 8(3):182-4. PubMed ID: 8814373
[TBL] [Abstract][Full Text] [Related]
39. Re-examination of clinical aspects of pharmacoeconomic analysis.
Rubenstein EB; Elting LS
Am J Hosp Pharm; 1994 Dec; 51(23):2970-3. PubMed ID: 7879813
[No Abstract] [Full Text] [Related]
40. Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?
Blower P; Aapro M
Br J Cancer; 2002 May; 86(10):1662-3; author reply 1664. PubMed ID: 12085221
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
